Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to Intravenous Immunoglobulin Therapy: Report of an Open-label Case Series

REFERENCES

1. 1.↵
   1. Kawasaki T,
   2. Kosaki F,
   3. Okawa S,
   4. Shigematsu I,
   5. Yanagawa H

   . A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271–6.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Kobayashi N,
   2. Mori M,
   3. Kobayashi Y,
   4. Miyamae T,
   5. Imagawa T,
   6. Okuyama T,
   7. et al.

   Intravenous gamma-globulin therapy improves hypercytokinemia in the acute phase of Kawasaki disease. Mod Rheumatol 2004;14:447–52.

   OpenUrlCrossRef
3. 3.↵
   1. Burns JC,
   2. Mason WH,
   3. Hauger SB,
   4. Janai H,
   5. Bastian JF,
   6. Wohrley JD,
   7. et al.

   Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662–7.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Burns JC,
   2. Best BM,
   3. Mejias A,
   4. Mahony L,
   5. Fixler DE,
   6. Jafri HS,
   7. et al.

   Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008;153:833–8.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Ayusawa M,
   2. Sonobe T,
   3. Uemura S,
   4. Ogawa S,
   5. Nakamura Y,
   6. Kioyosawa N,
   7. et al.

   Revision of diagnostic guidelines for Kawasaki disease (5th revised edition). Pediatr Intern 2005;47:232–4.

   OpenUrlCrossRef
6. 6.↵
   1. Mori M,
   2. Imagawa T,
   3. Yasui K,
   4. Kanaya A,
   5. Yokota S

   . Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000;137:177–80.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Imagawa T,
   2. Mori M,
   3. Miyamae T,
   4. Ito S,
   5. Nakamura T,
   6. Yasui K,
   7. et al.

   Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004;163:263–4.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Mori M,
   2. Imagawa T,
   3. Katakura S,
   4. Miyamae T,
   5. Okuyama K,
   6. Ito S,
   7. et al.

   Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol 2004;14:43–7.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Hashino K,
   2. Ishii M,
   3. Iemura M,
   4. Akagi T,
   5. Kato H

   . Re-treatment for immune globulin-resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211–7.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Newburger JW,
    2. Sleeper LA,
    3. McCrindle BW,
    4. Minich LL,
    5. Gersony W,
    6. Vetter VL,
    7. et al.

    Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007;356:663–75.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Miura M,
    2. Ohki H,
    3. Yoshiba S,
    4. Ueda H,
    5. Sugaya A,
    6. Satoh M,
    7. et al.

    Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005;90:1096–7.

    OpenUrlFREE Full Text
12. 12.↵
    1. Leung DYM,
    2. Geha RS,
    3. Newburger JW,
    4. Burns JC,
    5. Fiers W,
    6. Lapierre LA,
    7. et al.

    Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med 1986;164:1958–72.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Keane J,
    2. Gershon S,
    3. Wise RP,
    4. Mirabile-Levens E,
    5. Kasznica J,
    6. Schwieterman WD,
    7. et al.

    Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098–104.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Chung ES,
    2. Packer M,
    3. Lo KH,
    4. Fasanmade AA,
    5. Willerson JT; and
    6. Anti-TNF Therapy Against Congestive Heart Failure Investigators

    . Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failure. Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial. Circulation 2003;107:3133–40.

    OpenUrlAbstract/FREE Full Text